The Canine Oral Derm Landscape:
Zenrelia vs Apoquel vs Numelvi

For a decade, canine dermatology was effectively one company's category. Zoetis defined the oral JAK lane with Apoquel (2013) and the injectable anti-IL-31 lane with Cytopoint (2016), and everyone else played for the remainder.

H1 2026 ended that. In roughly ninety days, Merck Animal Health launched the first second-generation JAK inhibitor and Elanco brought a second monoclonal antibody to market, while its once-daily JAK continued to scale. The category is now a genuine three-company contest fought across two mechanisms and, within the JAK lane, competing claims about molecular generation. This brief maps what shipped, what it means commercially, and where each function should focus next.

The Category Map: Two Mechanisms, Three JAKs

The canine dermatology market now resolves into two mechanistic lanes plus a legacy tier, and the competitive story lives in how crowded each lane has become.

The oral JAK lane, now three deep

The JAK inhibitors are no longer one product. Each new entrant is explicitly positioned against the last:

• Apoquel (oclacitinib, Zoetis, FDA May 2013). The incumbent that built the category and still anchors it. Labeled for dogs at least 12 months of age.
• Zenrelia (ilunocitinib, Elanco, FDA September 2024). A once-daily JAK positioned head to head against Apoquel on non-inferiority and once-daily dosing from the start.
• Numelvi (atinvicitinib, Merck Animal Health, FDA February 25, 2026). Positioned as the first second-generation, JAK1-selective inhibitor, on selectivity, the youngest age label in the class, and shelf-life advantages.

Context: the injectable anti-IL-31 mAb lane, now two

This page is about the oral JAK fight. The antibody lane matters here because it shapes the portfolio each JAK lives inside, so it is summarized rather than taken apart. For the full head to head on those two, see The Derm Brief: Cytopoint vs Befrena.

• Cytopoint (lokivetmab, Zoetis, USDA December 2016). The incumbent biologic, a 4 to 8 week dosing interval and a multi-year, high-volume real-world record.
• Befrena (tirnovetmab, Elanco, USDA December 31, 2025, launched May 18, 2026). At least 6 to 8 weeks of itch relief, with no age or weight restriction on the label.

Legacy tier: cyclosporine (Atopica) and corticosteroids still hold real volume in cost-sensitive and specific clinical segments, but the competitive narrative has moved to JAKs and mAbs.

The Competitive Matrix

Five products, three companies, two mechanisms. What the public label and launch record actually say, as of August 2026.

The three tensions worth watching

1. The "generation" story in the JAK lane. Merck is not selling another JAK. It is selling a newer kind of JAK, leaning on JAK1 selectivity and second-generation framing borrowed from human medicine. That reframes Apoquel and Zenrelia as prior generation. Note that this is positioning, not a regulatory category: published literature also characterizes oclacitinib as JAK1-selective. Whether general-practice prescribers reward the distinction is the open commercial question of the half.

2. Safety-label history as commercial baggage. Zenrelia launched carrying vaccine-related Boxed Warning language, and Elanco worked through 2025 to narrow it. The September 2025 update removed the fatal vaccine-induced-disease language, but the Boxed Warning still directs discontinuation before vaccination and a withholding period after. Numelvi enters without that history and with its own precautions to manage. In a category where clinics ask "what is the catch," label cleanliness is a commercial asset, not just a regulatory footnote. Getting this detail wrong in the field is worse than not raising it.

3. The mAb interval framing. Befrena's at-least-6-to-8-week claim will be sold as extended protection. The honest counter is that Cytopoint's 4-week option is flexibility, the ability to calibrate frequency to a patient's severity, not a shortcoming. Same data, two narratives, and whoever frames it first in a given clinic tends to win it.

The Portfolio War: Three Companies, Three Plays

The single-product comparison misses the real move. Each company now walks into a dermatology conversation with a distinct posture.

Clinic Dynamics: How the Decision Actually Gets Made

Category decisions are not made on molecule specs. They are made through protocol inertia, staff workflow, client familiarity, inventory economics, and rep relationships. Three new entrants collide with all of it.

Protocol inertia is the incumbent's moat

Clinics running Apoquel and Cytopoint have reorder routines, practice-management reminders, staff training, and clients who have seen results. "It works" is the hardest position to dislodge. New entrants win most easily where no protocol is set yet.

The age-label opening

Numelvi's 6-month label and Befrena's no-age and no-weight label both reach patients earlier than the 12-month JAK incumbents. First-diagnosis, younger-dog visits are a genuine structural opening for the challengers, and the one segment where inertia does not protect the incumbent.

Will general practitioners buy "second generation"?

Selectivity and generational framing resonate cleanly with specialists. The commercial question is whether general practitioners, who write the majority of dermatology scripts, reward it or default to the familiar. This is the single most important adoption unknown of Numelvi's launch.

Questions your reps are getting right now

What Q2 Earnings Confirmed

When this brief was first drafted, the decisive signal was still ahead of us: the first quantified, public read on dermatology-segment impact. Elanco and Zoetis reported one day apart in August 2026. The number arrived, and it is large.

H1 Recap and H2 Outlook

The half that reset the category, and the signals that will decide who holds the gains.

What shipped

The four signals that decide H2

• Numelvi general-practice adoption. Does JAK1 selectivity translate into general-practice scripts, or stay a specialist story?
• Befrena velocity against Cytopoint defense. The first full quarter of penetration is the most predictive signal of the mAb lane's next three years.
• Share source. Are the new entrants pulling from Apoquel, from Cytopoint, or growing the category net new? Three different stories, three different responses.
• Whether the 5-point quarterly share decline repeats. One quarter is a data point. Two consecutive quarters at that rate is a trend line that reprices the category.

The Strategic Playbook

The dermatology response spans four functions. Here is where each should focus while the window is open.